BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35105685)

  • 1. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
    Calvi A; Tur C; Chard D; Stutters J; Ciccarelli O; Cortese R; Battaglini M; Pietroboni A; De Riz M; Galimberti D; Scarpini E; De Stefano N; Prados F; Barkhof F
    Neuroimage Clin; 2022; 35():103048. PubMed ID: 35598462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Preziosa P; Pagani E; Moiola L; Rodegher M; Filippi M; Rocca MA
    Mult Scler; 2021 Sep; 27(10):1520-1532. PubMed ID: 33183125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
    Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Barkhof F; Schoonheim MM; Strijbis EM; Vrenken H; Gallo A; Bisecco A; Ciccarelli O; Yiannakas M; Rovira A; Sastre-Garriga J; Palace J; Matthews L; Gass A; Eisele P; Lukas C; Bellenberg B; Margoni M; Preziosa P; Filippi M;
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):10-18. PubMed ID: 36171105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Arnold DL; Elliott C; Martin EC; Hyvert Y; Tomic D; Montalban X
    Neurology; 2024 Mar; 102(5):e208058. PubMed ID: 38335474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.
    Traboulsee A; Dehmeshki J; Peters KR; Griffin CM; Brex PA; Silver N; Ciccarrelli O; Chard DT; Barker GJ; Thompson AJ; Miller DH
    Mult Scler; 2003 Dec; 9(6):566-73. PubMed ID: 14664468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
    Calvi A; Clarke MA; Prados F; Chard D; Ciccarelli O; Alberich M; Pareto D; Rodríguez Barranco M; Sastre-Garriga J; Tur C; Rovira A; Barkhof F
    Mult Scler; 2023 Mar; 29(3):352-362. PubMed ID: 36515487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
    Calvi A; Carrasco FP; Tur C; Chard DT; Stutters J; De Angelis F; John N; Williams T; Doshi A; Samson RS; MacManus D; Gandini Wheeler-Kingshott CA; Ciccarelli O; Chataway J; Barkhof F;
    Neurology; 2022 Apr; 98(17):e1783-e1793. PubMed ID: 35277438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
    Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
    J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative T
    Harper JG; York EN; Meijboom R; Kampaite A; Thrippleton MJ; Kearns PKA; Valdés Hernández MDC; Chandran S; Waldman AD;
    Eur Radiol; 2024 Jun; 34(6):3826-3839. PubMed ID: 37943312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.
    Calvi A; Mendelsohn Z; Hamed W; Chard D; Tur C; Stutters J; MacManus D; Kanber B; Wheeler-Kingshott CAMG; Barkhof F; Prados F
    Eur J Neurol; 2024 Jan; 31(1):e16092. PubMed ID: 37823722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.